Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019.
Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T. Nakano M, et al. Among authors: harada m. Sci Rep. 2022 Jan 27;12(1):1517. doi: 10.1038/s41598-022-05444-z. Sci Rep. 2022. PMID: 35087153 Free PMC article.
Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study.
Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miuma S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, Torimura T. Ide T, et al. Among authors: harada m. Hepatol Int. 2019 May;13(3):293-301. doi: 10.1007/s12072-019-09939-2. Epub 2019 Feb 28. Hepatol Int. 2019. PMID: 30820753
Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.
Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakado S, Sakisaka S, Miuma S, Nakao K, Yoshimaru Y, Sasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T. Nakano M, et al. Among authors: harada m. Cancer Med. 2019 May;8(5):2646-2653. doi: 10.1002/cam4.2061. Epub 2019 Mar 22. Cancer Med. 2019. PMID: 30900818 Free PMC article.
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, Yoshizumi T, Itoh S, Yatsuhashi H, Bekki S, Ido A, Mawatari S, Honda K, Sugimoto R, Senju T, Takahashi H, Kuwashiro T, Maeshiro T, Nakamuta M, Aratake Y, Yamashita T, Otsuka Y, Matsumoto S, Sohda T, Shimose S, Murotani K, Tanaka Y. Niizeki T, et al. Among authors: harada m. Target Oncol. 2022 Nov;17(6):643-653. doi: 10.1007/s11523-022-00921-x. Epub 2022 Oct 22. Target Oncol. 2022. PMID: 36272060 Free PMC article.
POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33.
Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M. Hitomi Y, et al. Among authors: harada m. Sci Rep. 2019 Jan 14;9(1):102. doi: 10.1038/s41598-018-36490-1. Sci Rep. 2019. PMID: 30643196 Free PMC article.
Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Tateishi R, et al. J Gastroenterol. 2021 Mar;56(3):261-273. doi: 10.1007/s00535-020-01754-z. Epub 2021 Jan 11. J Gastroenterol. 2021. PMID: 33427937 Free PMC article.
[Alcohol-related liver disease].
Harada M, Honma Y, Shibata M. Harada M, et al. Nihon Shokakibyo Gakkai Zasshi. 2022;119(1):9-13. doi: 10.11405/nisshoshi.119.9. Nihon Shokakibyo Gakkai Zasshi. 2022. PMID: 35022376 Japanese. No abstract available.
[Recognition of infection, status of outpatient treatment, and treatment history before carcinogenesis in patients with viral hepatitis-associated liver cancer].
Shibata M, Minami S, Oe S, Miyagawa K, Honma Y, Onitsuka R, Senju M, Hiura M, Harada R, Abe S, Tabaru A, Harada M. Shibata M, et al. Among authors: harada r, harada m. Nihon Shokakibyo Gakkai Zasshi. 2016;113(10):1734-1742. doi: 10.11405/nisshoshi.113.1734. Nihon Shokakibyo Gakkai Zasshi. 2016. PMID: 27725462 Japanese.
3,862 results